bacteria

The Medicines Company subsidiary Rempex Pharmaceuticals has received a contract worth $90m from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of Carbavance, a combination of a carbapenem antibiotic with a novel beta-lactamase inhibitor, designed to treat multi-drug resistant (MDR) gram-negative infections.

The BARDA contract, a cost-sharing agreement, includes non-clinical development activities, clinical studies, manufacturing, and related regulatory activities designed to gain US approval of Carbavance for the treatment of serious gram-negative infections.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company said that clinical studies are also planned to evaluate the potential usefulness of Carbavance to treat certain gram-negative bioterrorism agents.

The Medicines Company/Rempex Pharmaceuticals senior vice-president Michael Dudley said: "We are grateful that BARDA has recognised the potential usefulness of Carbavance for management of MDR gram-negative pathogens that present an urgent threat to the US healthcare system."

"This mutual commitment with BARDA is intended to save lives, alleviate suffering and contribute to the economics of healthcare by attacking gram-negative pathogens with Carbavance."

Included in the contract is an initial commitment of $19.8m and subsequent option periods over five years that, if completed, would bring the total value of the award to $90m.

See Also:

The Medicines Company chairman and CEO Clive Meanwell said: "With acute and intensive care hospitals in the United States facing rapid and increasing antibacterial resistance, this mutual commitment with BARDA is intended to save lives, alleviate suffering and contribute to the economics of healthcare by attacking gram-negative pathogens with Carbavance."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Carbavance is a combination of a carbapenem antibiotic (RPX2003) combined with a second drug (RPX7009) that acts as an inhibitor of bacterial beta-lactamases.

It is currently under development for the treatment of gram-negative bacteria, Escherichia coli, Klebsiella sp, Acinetobacter sp, and Pseudomonas aeruginosa.

Image: Carbavance is administered through intravenous route. Photo: courtesy of freedigitalphotos.net.